News

Mursla unveils new bead-nanochip technology for ultrasensitive and high throughput exosome detection

Novel technology further establishes Mursla’s capabilities to uniquely analyse exosome biology for clinical translation

Mursla gains mentorship from Roche Diagnostics for pilot study in cirrhotic/liver cancer patients

Access to Roche Diagnostics’ expertise in the UK secured in recognition of Mursla’s differentiated value proposition for liquid biopsy

Mursla presents its new logo to better reflect its core technology

New logo symbolises the secretion of an exosome from its parental cell along with its markers of origin.

Mursla announces key appointments to Advisory Board

Key opinion leaders in the fields of exosomes, liquid biopsy and liver disease support Mursla’s ambition

Mursla granted patents for novel nanoelectronics detection system for exosomes

Mursla has been granted two patents for its novel nanoelectronics-based sensitive detection method for exosomes.

Mursla helping on COVID-19

Mursla is dedicating resources to help improve COVID-19 diagnostics & therapeutics solutions. We are currently capitalising upon our...

Cambridge Tech Awards 2019: Mursla among the #OneToWatch

Mursla was selected again as one of the most exciting tech companies to follow in the Cambridge cluster. https://www.cambridgeindependent...

Award for innovation in Cambridgeshire and East of England

We are delighted to have won the #onetowatch award as one of the most innovative companies in Cambridgeshire and East of England. The...

Blog

Want to partner with us?